Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acridine Orange. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.52 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.41 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.41 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.41 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.41 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.41 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.41 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.41 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.39 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acridine Orange SCHEMBL29837411 | 1.00 | TERT (0.87) | TERTAPPEGFRAPAF1ALDH1A1 | |
| Acridine Orange SCHEMBL9985168 | 1.00 | TERT (0.87) | TERTAPPEGFRAPAF1ALDH1A1 | |
| Acridine Orange SCHEMBL31143792 | 0.98 | TERT (0.91) | TERTAPPEGFRAPAF1ALDH1A1 | |
| Acridine Orange SCHEMBL5520688 | 0.96 | TERT (0.87) | TERTAPPEGFRAPAF1ALDH1A1 | |
| Acridine Orange SCHEMBL30153753 | 0.96 | TERT (0.95) | TERTAPPEGFRAPAF1ALDH1A1 | |
| Acridine Orange SCHEMBL22071 | 0.96 | TERT (0.95) | TERTAPPEGFRAPAF1ALDH1A1 | |
| Acridine Orange SCHEMBL8408019 | 0.93 | APP (0.91) | TERTAPPEGFRAPAF1ALDH1A1 | |
| Acridine Orange SCHEMBL5859399 | 0.93 | TERT (0.91) | TERTAPPEGFRAPAF1ALDH1A1 | |
| Acridine Orange SCHEMBL29361720 | 0.93 | TERT (1.00) | TERTAPPEGFRAPAF1ALDH1A1 | |
| Acridine Orange SCHEMBL297155 | 0.93 | TERT (1.00) | TERTAPPEGFRAPAF1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181787-A | Method for rapidly detecting product after PCR amplification | 广州医科大学附属第一医院（广州呼吸中心） | 2022-10-14 | — | — | CN | claimed |
| US-20240041787-A1 | PHOTOSENSITIZER MOLECULE AND USE THEREOF IN INCREASING TUMOR RETENTION TIME AND ENHANCING TREATMENT OF LARGE-VOLUME TUMORS | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2024-02-08 | — | — | US | disclosed |
| CN-115181787-A | Method for rapidly detecting product after PCR amplification | 广州医科大学附属第一医院（广州呼吸中心） | 2022-10-14 | — | — | CN | disclosed |
| US-20220119569-A1 | Curable and Solvent Soluble Formulations and Methods of Making and Using Therof | POLY6 TECHNOLOGIES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20200062877-A1 | Curable and Solvent Soluble Formulations and Methods of Making and Using Therof | POLY6 TECHNOLOGIES, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10184927-B2 | Method for measuring polymer concentration in water systems | ECOLAB USA INC. (US) | 2019-01-22 | — | — | US | disclosed |
| WO-2018156766-A2 | CURABLE AND SOLVENT SOLUBLE FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | POLY6 TECHNOLOGIES, INC. (US) | 2018-08-30 | — | — | WO | disclosed |
| US-20170191975-A1 | Method for Measuring Polymer Concentration in Water Systems | ECOLAB USA INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9599566-B2 | Method for measuring polymer concentration in water systems | ECOLAB USA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160290929-A1 | Method for Measuring Polymer Concentration in Water Systems | ECOLAB USA INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-7122572-B2 | For use in Hydrogen Bonding Liquid Chromatography, environmental remediation by removal of undesired ions or neutral molecules, removal of phosphate for kidney dialysis, drug delivery, separation | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2006-10-17 | — | — | US | disclosed |
| US-7041819-B2 | Halogenated calixpyrroles and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-09 | — | — | US | disclosed |
| US-6984734-B2 | Cyclo[n]pyrroles and methods thereto | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-01-10 | — | — | US | disclosed |
| US-20030229131-A1 | Cyclo[n]pyrroles and methods thereto | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-12-11 | — | — | US | disclosed |
| WO-2003018548-A2 | HALOGENATED CALIXPYRROLES, CALIXPYRIDINOPYRROLES AND CALIXPYRIDINES, AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020115566-A1 | Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-08-22 | — | — | US | disclosed |
| US-20020026047-A1 | Calixpyrroles, calixpyridinopyrroles, and calixpyridines | BOARD OF REGENTS, THE | 2002-02-28 | — | — | US | disclosed |
| US-6262257-B1 | SELECTIVE ION- AND NEUTRAL MOLECULE-BINDING AGENTS FORMING SUPRAMOLECULAR ENSEMBLES, AND ION- AND NEUTRAL MOLECULE-SEPARATION AGENTS | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2001-07-17 | — | — | US | disclosed |
| EP-0891364-A1 | CALIXPYRROLES, CALIXPYRIDINOPYRROLES AND CALIXPYRIDINES | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997037995-A1 | CALIXPYRROLES, CALIXPYRIDINOPYRROLES AND CALIXPYRIDINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041787-A1 | PHOTOSENSITIZER MOLECULE AND USE THEREOF IN INCREASING TUMOR RETENTION TIME AND ENHANCING TREATMENT OF LARGE-VOLUME TUMORS | ANXA1, BID, ANXA11 | EGFR 482/4885CHRM2 4714/4885HTR1A 3852/4885 |
| US-20030229131-A1 | Cyclo[n]pyrroles and methods thereto | PPOX, QPCT, PPIE | EGFR 4628/4885CHRM2 1595/4885HTR1A 3440/4885 |
| US-20020115566-A1 | Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof | CALD1, CALU, CLASP1 | EGFR 1984/4885CHRM2 2042/4885HTR1A 2646/4885 |
| US-20020026047-A1 | Calixpyrroles, calixpyridinopyrroles, and calixpyridines | CALD1, DAP3, CALR | EGFR 918/4885CHRM2 2512/4885HTR1A 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.